Chandrashekhar A Kubal

Dr. Chandrashekhar A Kubal

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Kidney International
Verified
Journal Article
Closed access
KEKevin S. Eardley
Kevin S. Eardley
CKChandrashekhar A Kubal
Chandrashekhar A Kubal
DZDaniel Zehnder
Daniel Zehnder
MQMarcus Quinkler
Marcus Quinkler
JLJulia Lepenies
Julia Lepenies
PCPaul Cockwell
Paul Cockwell

19 August 2008 in Nature Clinical Practice Cardiovascular Medicine
Verified
Journal Article
Closed access
PDF file
KAKeng-Leong Ang
Keng-Leong Ang
DCDerek Chin
Derek Chin
FLFrancisco Leyva
Francisco Leyva
PFPaul Foley
Paul Foley
CKChandrashekhar A Kubal
Chandrashekhar A Kubal
MGManuel Galiñanes
Manuel Galiñanes

1 June 2012 in Annals of Surgery
Verified
Journal Article
Closed access
RVRodrigo M. Vianna
Rodrigo M. Vianna
RMRichard S. Mangus
Richard S. Mangus
CKChandrashekhar A Kubal
Chandrashekhar A Kubal
JFJonathan A. Fridell
Jonathan A. Fridell
TBThiago Beduschi
Thiago Beduschi
ATA. Joseph Tector
A. Joseph Tector
Objective: To evaluate the clinical outcomes of multivisceral transplantation (MVT) in the setting of diffuse thrombosis of the portomesenteric venous system. Background: Liver transplantation (LT) in the face of cirrhosis and diffuse portomesenteric thrombosis (PMT) is controversial and contraindicated in many transplant centers. LT using alternative techniques such as portocaval hemitransposition fails to eliminate complications of portal hypertension. MVT replaces the liver and the thrombosed portomesenteric system. Methods: A database of intestinal transplant patients was maintained with prospective analysis of outcomes. The diagnosis of diffuse PMT was established with dual-phase abdominal computed tomography or magnetic resonance imaging with venous reconstruction. Results: Twenty-five patients with grade IV PMT received 25 MVT. Eleven patients underwent simultaneous cadaveric kidney transplantation. Biopsy-proven acute cellular rejection was noted in 5 recipients, which was treated successfully. With a median follow-up of 2.8 years, patient and graft survival were 80%, 72%, and 72% at 1, 3, and 5 years, respectively. To date, all survivors have good graft function without any signs of residual/recurrent features of portal hypertension. Conclusions: MVT can be considered as an option for the treatment of patients with diffuse PMT. MVT is the only procedure that completely reverses portal hypertension and addresses the primary disease while achieving superior survival results in comparison to the alternative options.

1 November 2017 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
PDF file
RMRichard S. Mangus
Richard S. Mangus
WBWeston J. Bush
Weston J. Bush
CMChristina Miller
Christina Miller
CKChandrashekhar A Kubal
Chandrashekhar A Kubal

1 January 2013 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
RMRichard S. Mangus
Richard S. Mangus
ATA. Joseph Tector
A. Joseph Tector
CKChandrashekhar A Kubal
Chandrashekhar A Kubal
JFJonathan A. Fridell
Jonathan A. Fridell
RVRodrigo M. Vianna
Rodrigo M. Vianna

1 May 2005 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
CKChandrashekhar A Kubal
Chandrashekhar A Kubal
ASArun K. Srinivasan
Arun K. Srinivasan
AGAntony D. Grayson
Antony D. Grayson
BFBrian M. Fabri
Brian M. Fabri
JCJohn A.C. Chalmers
John A.C. Chalmers